NASDAQ: POAI
Predictive Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for POAI

Based on 1 analyst offering 12 month price targets for Predictive Oncology Inc

Min Forecast
$3.00+109.79%
Avg Forecast
$3.00+109.79%
Max Forecast
$3.00+109.79%

Should I buy or sell POAI stock?

Based on 1 analyst offering ratings for Predictive Oncology Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their POAI stock forecasts and price targets.

POAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-19

1 of 1

Forecast return on equity

Is POAI forecast to generate an efficient return?

Company
155.92%
Industry
8.38%
Market
89.33%
POAI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is POAI forecast to generate an efficient return on assets?

Company
40.9%
Industry
4.95%
POAI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

POAI earnings per share forecast

What is POAI's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.13
Avg 2 year Forecast
$0.08
Avg 3 year Forecast
$0.27

POAI revenue forecast

What is POAI's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$9.3M+576.54%
Avg 2 year Forecast
$15.5M+1,020.31%
Avg 3 year Forecast
$24.0M+1,638.11%
POAI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

POAI revenue growth forecast

How is POAI forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
157.59%
Industry
11.62%
Market
11.68%
POAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
POAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

POAI vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
POAI$1.43$3.00+109.79%Buy
BNGO$5.22$60.00+1,049.43%Hold
MHUA$0.35N/AN/A
LUCY$5.08N/AN/A
EKSO$0.58$5.50+856.52%Strong Buy

Predictive Oncology Stock Forecast FAQ

Is Predictive Oncology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: POAI) stock is to Buy POAI stock.

Out of 1 analyst, 0 (0%) are recommending POAI as a Strong Buy, 1 (100%) are recommending POAI as a Buy, 0 (0%) are recommending POAI as a Hold, 0 (0%) are recommending POAI as a Sell, and 0 (0%) are recommending POAI as a Strong Sell.

If you're new to stock investing, here's how to buy Predictive Oncology stock.

What is POAI's earnings growth forecast for 2025-2027?

(NASDAQ: POAI) Predictive Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 17.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.63%.

Predictive Oncology's earnings in 2025 is -$13,970,141.On average, 1 Wall Street analyst forecast POAI's earnings for 2025 to be -$866,709, with the lowest POAI earnings forecast at -$866,709, and the highest POAI earnings forecast at -$866,709. On average, 1 Wall Street analyst forecast POAI's earnings for 2026 to be $533,359, with the lowest POAI earnings forecast at $533,359, and the highest POAI earnings forecast at $533,359.

In 2027, POAI is forecast to generate $1,800,088 in earnings, with the lowest earnings forecast at $1,800,088 and the highest earnings forecast at $1,800,088.

What is POAI's revenue growth forecast for 2025-2027?

(NASDAQ: POAI) Predictive Oncology's forecast annual revenue growth rate of 157.59% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 11.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.68%.

Predictive Oncology's revenue in 2025 is $1,379,086.On average, 1 Wall Street analysts forecast POAI's revenue for 2025 to be $62,203,045, with the lowest POAI revenue forecast at $62,203,045, and the highest POAI revenue forecast at $62,203,045. On average, 1 Wall Street analysts forecast POAI's revenue for 2026 to be $103,005,042, with the lowest POAI revenue forecast at $103,005,042, and the highest POAI revenue forecast at $103,005,042.

In 2027, POAI is forecast to generate $159,807,822 in revenue, with the lowest revenue forecast at $159,807,822 and the highest revenue forecast at $159,807,822.

What is POAI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: POAI) forecast ROA is 40.9%, which is higher than the forecast US Medical Instruments & Supplies industry average of 4.95%.

What is POAI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year POAI price target, the average POAI price target is $3.00, with the highest POAI stock price forecast at $3.00 and the lowest POAI stock price forecast at $3.00.

The Wall Street analyst predicted that Predictive Oncology's share price could reach $3.00 by Aug 19, 2025. The average Predictive Oncology stock price prediction forecasts a potential upside of 109.79% from the current POAI share price of $1.43.

What is POAI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: POAI) Predictive Oncology's current Earnings Per Share (EPS) is -$3.05. On average, analysts forecast that POAI's EPS will be -$0.13 for 2025, with the lowest EPS forecast at -$0.13, and the highest EPS forecast at -$0.13. On average, analysts forecast that POAI's EPS will be $0.08 for 2026, with the lowest EPS forecast at $0.08, and the highest EPS forecast at $0.08. In 2027, POAI's EPS is forecast to hit $0.27 (min: $0.27, max: $0.27).

What is POAI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: POAI) forecast ROE is 155.92%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.